tradingkey.logo

Ligand Pharmaceuticals Inc

LGND
View Detailed Chart

169.830USD

+4.420+2.67%
Close 09/18, 16:00ETQuotes delayed by 15 min
3.30BMarket Cap
LossP/E TTM

Ligand Pharmaceuticals Inc

169.830

+4.420+2.67%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.67%

5 Days

+1.66%

1 Month

+10.82%

6 Months

+59.89%

Year to Date

+58.50%

1 Year

+63.80%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
10 / 175
Overall Ranking
67 / 4721
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
183.125
Target Price
+10.71%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 4.03M.%!(EXTRA int=2)
Undervalued
The company’s latest PE is -41.55, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 19.71M shares, decreasing 3.61% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.08M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.11.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Ticker SymbolLGND
CompanyLigand Pharmaceuticals Inc
CEOMr. Todd C. Davis
Websitehttps://www.ligand.com/
KeyAI